VesiGel (mitomycin intravesicular) / UroGen  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
VesiGel (mitomycin intravesicular) / UroGen
NCT05136898: Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Completed
3
8
US
UGN-102, UGN-102 (mitomycin) for intravesical solution
UroGen Pharma Ltd.
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
02/23
02/23
ATLAS, NCT04688931: A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Terminated
3
282
Europe, US, RoW
UGN-102, UGN-102 (mitomycin) for intravesical solution, TURBT, Transurethral resection of bladder tumors
UroGen Pharma Ltd.
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
03/23
03/23
2020-003541-11: An Open Study of the Efficacy, Durability, and Safety of a new drug in Patients with Bladder Cancer (ATLAS)

Not yet recruiting
3
632
Europe, RoW
UGN-102 (Mitomycin) for Solution, UGN-102, Powder for intravesical solution
UroGen Pharma Ltd., UroGen Pharma Ltd.
Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Diseases [C] - Cancer [C04]
 
 
ENVISION, NCT05243550 / 2021-005948-29: A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

Active, not recruiting
3
220
Europe, US, RoW
UGN-102, UGN-102 (mitomycin) for intravesical solution
UroGen Pharma Ltd.
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
04/23
02/28
UTOPIA, NCT06331299: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Not yet recruiting
3
87
NA
UGN-103, UGN-103 (mitomycin) for intravesical solution
UroGen Pharma Ltd.
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
03/25
03/26

Download Options